Xiang Yan Selected Research

Latent Autoimmune Diabetes in Adults

1/2020	Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.
6/2010	[Relation between insulin resistance and glutamic acid decarboxylase antibody titers in latent autoimmune diabetes in adults].
7/2009	Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).
1/2005	Metabolic syndrome in adult-onset latent autoimmune diabetes.
6/2004	[Islet beta cell function in latent autoimmune diabetes in adults with islet cell antibodies].
12/2003	[Metabolic syndrome and latent autoimmune diabetes in adults].
11/2003	Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults.
1/2003	[Identification of the two subtypes of latent autoimmune diabetes in adults by glutamic acid decarboxylase 65 antibody titers].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiang Yan Research Topics

Disease

23	Neoplasms (Cancer) 05/2022 - 04/2011
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022 - 01/2014
15	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/2022 - 01/2003
11	Type 2 Diabetes Mellitus (MODY) 03/2022 - 01/2003
10	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 12/2004
9	Insulin Resistance 10/2022 - 01/2005
8	Latent Autoimmune Diabetes in Adults 01/2020 - 01/2003
6	Inflammation (Inflammations) 03/2022 - 03/2005
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 06/2010
6	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2012
5	Fibrosis (Cirrhosis) 01/2021 - 01/2015
5	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2019
5	Infections 02/2016 - 09/2010
4	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2018
4	Stomach Neoplasms (Stomach Cancer) 06/2019 - 01/2014
3	Body Weight (Weight, Body) 10/2022 - 08/2019
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 12/2003
3	Carcinoma (Carcinomatosis) 03/2021 - 01/2014
3	Obesity 10/2020 - 01/2019
3	Pain (Aches) 01/2020 - 06/2017
3	Adenocarcinoma 01/2020 - 03/2012
3	Adenocarcinoma of Lung 01/2019 - 01/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 02/2015 - 11/2010
3	Hypertension (High Blood Pressure) 08/2013 - 01/2003
2	Diabetes Mellitus 06/2022 - 01/2022
2	Hypoglycemia (Reactive Hypoglycemia) 06/2022 - 08/2010
2	Carcinogenesis 01/2021 - 12/2016
2	Diabetes Complications 01/2021 - 11/2003
2	Parkinson Disease (Parkinson's Disease) 11/2020 - 01/2019
2	Ureteral Obstruction 11/2019 - 01/2015
2	Hemorrhage 01/2019 - 06/2010
2	Wounds and Injuries (Trauma) 01/2018 - 08/2013
2	Anemia 01/2017 - 01/2013
2	Acute Kidney Injury (Acute Renal Failure) 11/2016 - 01/2016
2	Ischemia 11/2016 - 09/2016
2	Nausea 06/2015 - 08/2010

Drug/Important Bio-Agent (IBA)

13	Insulin (Novolin)FDA Link 10/2022 - 01/2003
11	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2022 - 01/2003
8	ErbB Receptors (EGF Receptor)IBA 05/2022 - 01/2014
6	Blood Glucose (Blood Sugar)IBA 06/2022 - 07/2010
6	AutoantibodiesIBA 01/2022 - 11/2003
4	LipidsIBA 10/2022 - 12/2005
4	Messenger RNA (mRNA)IBA 10/2022 - 12/2016
4	Insulin Glargine (Lantus)FDA Link 06/2022 - 07/2008
4	AntigensIBA 01/2022 - 06/2012
4	Pharmaceutical PreparationsIBA 01/2022 - 02/2016
4	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2014
4	C-PeptideIBA 01/2021 - 01/2003
4	Immune Checkpoint InhibitorsIBA 12/2020 - 01/2019
3	dacomitinibIBA 05/2022 - 01/2022
3	CollagenIBA 01/2021 - 01/2015
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2020 - 01/2014
3	AntibodiesIBA 10/2020 - 06/2004
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2020 - 07/2010
3	Proteins (Proteins, Gene)FDA Link 10/2020 - 12/2004
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2020
3	Gemcitabine FDA Link 08/2019 - 01/2015
3	Cisplatin (Platino)FDA LinkGeneric 08/2019 - 08/2015
3	SmokeIBA 01/2017 - 08/2013
3	Hemoglobins (Hemoglobin)IBA 01/2013 - 01/2003
2	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 01/2019
2	Dietary Fiber FDA Link 10/2022 - 01/2020
2	LY2963016 insulin glargineIBA 06/2022 - 10/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2017
2	ZincIBA 01/2022 - 10/2010
2	Zinc Transporter 8IBA 01/2022 - 10/2010
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 01/2014
2	CholesterolIBA 01/2021 - 01/2019
2	Hematoxylin (Haematoxylon)IBA 01/2021 - 01/2014
2	Vitamin D FDA LinkGeneric 01/2021 - 07/2009
2	CalciumIBA 01/2021 - 01/2021
2	Small Interfering RNA (siRNA)IBA 10/2020 - 04/2013
2	Tumor Biomarkers (Tumor Markers)IBA 01/2020 - 10/2018
2	Peptides (Polypeptides)IBA 01/2020 - 01/2018
2	Long Noncoding RNAIBA 01/2020 - 01/2018
2	ParaffinIBA 01/2019 - 01/2019
2	NAD (NADH)IBA 01/2019 - 12/2008
2	EnzymesIBA 01/2019 - 01/2018
2	sodium bisulfide (NaHS)IBA 01/2018 - 08/2013
2	Biological ProductsIBA 01/2018 - 12/2016
2	Imidazoline ReceptorsIBA 12/2017 - 06/2017
2	Formaldehyde (Formol)FDA Link 12/2017 - 06/2017
2	Adrenergic Receptors (Adrenergic Receptor)IBA 12/2017 - 06/2017
2	Dexmedetomidine FDA Link 12/2017 - 06/2017
2	SurvivinIBA 04/2017 - 12/2016
2	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2017 - 08/2013
2	Docetaxel (Taxotere)FDA Link 01/2017 - 02/2016
2	Therapeutic UsesIBA 01/2017 - 06/2015
2	Folic Acid (Vitamin M)FDA LinkGeneric 11/2016 - 01/2016
2	tanshinoneIBA 11/2016 - 01/2016
2	Complement System Proteins (Complement)IBA 10/2015 - 09/2005

Therapy/Procedure

19	Therapeutics 03/2022 - 12/2005
6	Immunotherapy 01/2022 - 03/2012
5	Nephrectomy 01/2021 - 06/2010
5	Drug Therapy (Chemotherapy) 01/2020 - 03/2012
4	Radiofrequency Ablation 07/2016 - 04/2011
4	Ureteroscopes 02/2015 - 03/2006
3	Cryosurgery 06/2015 - 06/2010
3	Catheters 02/2015 - 11/2010
2	Glycemic Control 12/2018 - 04/2013